Vyleesi Regulatory Status: US, EU, Canada, UK

United States: Full FDA Approval Since 2019

The FDA approved bremelanotide on June 21, 2019, under the brand name Vyleesi, making it the second drug ever approved for HSDD in premenopausal women [1]. The approval was based on two randomized, double-blind, placebo-controlled Phase III trials (RECONNECT 1 and RECONNECT 2) enrolling 1,247 premenopausal women with acquired, generalized HSDD [2]. Flibanserin (Addyi), approved in 2015, was the first.

The FDA's approval letter specified that bremelanotide carries a boxed warning for transient increases in blood pressure. Systolic pressure rose by a mean of 3 mmHg and diastolic by 2 mmHg following injection in clinical trials. The label contraindicates use in patients with uncontrolled hypertension or known cardiovascular disease [1].

Palatin Technologies developed the molecule. AMAG Pharmaceuticals held the U.S. commercial license until its acquisition by Covis Pharma Group in 2022. Prescribing data from IQVIA shows that Vyleesi uptake has remained modest compared to flibanserin, partly due to the subcutaneous injection route and out-of-pocket costs that can exceed $900 per month without insurance coverage.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledged bremelanotide as a treatment option, noting that clinicians should weigh the on-demand dosing advantage against the injection route [3].

European Union: No Marketing Authorization

Bremelanotide has not been submitted for marketing authorization to the European Medicines Agency (EMA). No centralized or decentralized procedure application appears in the EMA's public register of applications as of May 2026.

Several factors explain this gap. HSDD as a diagnostic category has faced more scrutiny in Europe than in the United States. The European regulatory environment historically applied stricter thresholds for patient-reported outcome (PRO) endpoints in sexual medicine, and the EMA's Committee for Medicinal Products for Human Use (CHMP) has not published guidance specifically addressing HSDD drug development [4].

Palatin Technologies stated in its 2020 annual report (SEC 10-K filing) that it was "evaluating regulatory pathways in ex-U.S. markets" but disclosed no timeline for an EMA submission. The company's subsequent filings through 2025 did not reference active European regulatory plans.

European clinicians treating HSDD typically rely on off-label testosterone therapy. The International Society for the Study of Women's Sexual Health (ISSWSH) and the International Menopause Society have both published position statements supporting transdermal testosterone for HSDD in postmenopausal women, but no approved testosterone product for women exists in Europe either [5].

Canada: Not Approved

Health Canada has not approved bremelanotide. The Health Canada Drug Product Database contains no listing for bremelanotide or Vyleesi as of May 2026. No Notice of Compliance (NOC) or conditional approval has been issued.

Canadian prescribers who wish to use bremelanotide must apply through Health Canada's Special Access Programme (SAP), which permits access to non-marketed drugs for patients with serious or life-threatening conditions when conventional therapies have failed. HSDD does not typically meet the "serious or life-threatening" threshold required by SAP, which limits this pathway in practice.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) published clinical practice guidelines on female sexual health in 2018. These guidelines predate bremelanotide's FDA approval and do not mention the drug. Updated guidance is expected but has not been published [6].

Canada's Patented Medicine Prices Review Board (PMPRB) pricing framework could also affect commercial viability. The PMPRB benchmarks drug prices against international reference countries, and the absence of approvals in other comparator nations (France, Germany, Italy, Sweden, Switzerland, the UK) would complicate the pricing review.

United Kingdom: Not Licensed

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has not licensed bremelanotide. Post-Brexit, the MHRA operates independently from the EMA, and no application for bremelanotide appears in the MHRA's public assessment reports.

British prescribers managing HSDD follow guidance from the British Society for Sexual Medicine (BSSM), which published a position statement in 2018 endorsing off-label transdermal testosterone as first-line pharmacotherapy for HSDD in postmenopausal women [7]. The BSSM statement does not address bremelanotide.

The National Institute for Health and Care Excellence (NICE) has not conducted a technology appraisal for bremelanotide. Without a marketing authorization, NICE cannot initiate a formal health technology assessment (HTA). Even if approved, the drug would face a cost-effectiveness hurdle: NICE's standard willingness-to-pay threshold of £20,000 to £30,000 per quality-adjusted life year (QALY) is difficult to meet for PRO-driven sexual health endpoints, which typically show moderate effect sizes.

How Bremelanotide Works: Melanocortin Receptor Activation

Bremelanotide is a synthetic cyclic peptide that activates melanocortin-4 receptors (MC4R) in the central nervous system. This is distinct from flibanserin, which acts on serotonin receptors.

MC4R is expressed in hypothalamic nuclei involved in sexual arousal and reward processing. Preclinical studies in rat models demonstrated that MC4R activation increased solicitation behaviors in female subjects, independent of hormonal status [8]. The melanocortin system intersects with dopaminergic and oxytocinergic pathways, both of which contribute to sexual motivation.

The drug is administered as a 1.75 mg subcutaneous injection via a single-use autoinjector. Peak plasma concentration occurs approximately 1 hour post-injection. The elimination half-life is roughly 2.7 hours. Bremelanotide is metabolized by hydrolysis and has no significant cytochrome P450 interactions, which simplifies co-prescribing [1].

A key pharmacological distinction: bremelanotide does not affect hormonal axes. It does not alter estrogen, progesterone, or testosterone levels. This separates it mechanistically from testosterone-based therapies and from flibanserin's serotonergic mechanism. The FDA's clinical pharmacology review confirmed no clinically meaningful changes in reproductive hormones across the Phase III program [1].

Clinical Evidence: The RECONNECT Trials

The two RECONNECT trials (NCT02338960 and NCT02338986) were identically designed, randomized, double-blind, placebo-controlled studies conducted across 110 U.S. sites [2]. Combined enrollment reached 1,247 premenopausal women with acquired, generalized HSDD diagnosed by the Decreased Sexual Desire Screener (DSDS).

Participants self-administered bremelanotide 1.75 mg or placebo subcutaneously as needed for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Function Index-desire domain (FSFI-d) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score.

Results were statistically significant on both co-primary endpoints. The FSFI-d score improved by 0.5 points over placebo (P<0.001). The FSDS-DAO distress score decreased by 0.7 points over placebo (P<0.001). Responder analysis showed that 34.6% of bremelanotide-treated women achieved a clinically meaningful improvement in desire versus 22.8% on placebo [2].

The most common adverse event was nausea, occurring in 40% of bremelanotide patients versus 1% on placebo. Nausea diminished with repeated dosing: by dose 5 or 6, the incidence dropped below 10%. Injection site reactions occurred in 6% of active-treatment patients. Skin hyperpigmentation, primarily facial, appeared in 1% of patients, consistent with melanocortin pathway activation [2].

Dr. Sheryl Kingsberg, lead investigator for the RECONNECT program, stated in 2019: "The on-demand dosing model is fundamentally different from a daily pill. Women can choose to use it when they want to, which aligns with how many patients think about managing this condition" [9].

Regulatory Comparison: Bremelanotide vs. Flibanserin

Two drugs are FDA-approved for premenopausal HSDD. Their regulatory journeys differed sharply.

Flibanserin (Addyi) was rejected twice by the FDA (in 2010 and 2013) before approval in August 2015. The FDA required a Risk Evaluation and Mitigation Strategy (REMS) due to severe hypotension and syncope when combined with alcohol [10]. Bremelanotide's approval in 2019 did not require a REMS program, though the blood pressure warning was included in the label.

Flibanserin requires daily dosing (100 mg oral, taken at bedtime) regardless of planned sexual activity. Bremelanotide's on-demand model means patients use the drug only when desired. On the other hand, bremelanotide requires subcutaneous injection, while flibanserin is an oral tablet.

Neither drug has been approved outside the United States as of 2026. Flibanserin received marketing authorization in no additional major regulatory jurisdiction. This reflects a broader pattern: HSDD pharmacotherapy faces commercial and regulatory obstacles in markets outside the U.S. [5].

Why Global Expansion Has Stalled

Three overlapping barriers explain the limited geographic reach of bremelanotide approval.

Diagnostic ambiguity. HSDD was listed as a distinct diagnosis in the DSM-IV-TR but was merged into Female Sexual Interest/Arousal Disorder (FSIAD) in the DSM-5 (2013). The ICD-11 retains "hypoactive sexual desire dysfunction" as a code (HA00), but the DSM-5 change created uncertainty about patient selection for clinical trials designed around HSDD criteria [4].

Commercial viability. Bremelanotide's U.S. launch revenue underperformed expectations. AMAG Pharmaceuticals reported only $2.2 million in Vyleesi net revenue for the full year 2020. The injectable route, nausea profile, and limited insurance coverage contributed to low adoption. A manufacturer pursuing ex-U.S. approval must weigh regulatory filing costs (typically $5 million to $15 million per jurisdiction) against projected uptake [11].

Payer resistance. Health technology assessment bodies in Canada (CADTH), the UK (NICE), Australia (PBAC), and Germany (G-BA) apply formal cost-effectiveness analyses. PRO-based sexual health endpoints yield smaller QALY gains than endpoints like mortality reduction or disease remission, making favorable HTA outcomes difficult.

Palatin Technologies' 2024 10-K filing referenced ongoing discussions with potential licensing partners for ex-U.S. territories but disclosed no signed agreements or submission timelines.

What Patients in Non-U.S. Markets Can Do

Women with HSDD in Europe, Canada, and the UK have limited pharmacological options. Off-label transdermal testosterone (typically 300 mcg/day via compounded cream or one-tenth of a male patch) is the most commonly prescribed pharmacotherapy. The Global Position Statement on Testosterone Therapy for Women, published in 2019, endorsed testosterone supplementation for postmenopausal HSDD with appropriate monitoring of total testosterone levels [12].

For premenopausal women specifically, evidence supporting testosterone is weaker. The Endocrine Society recommends against routine testosterone therapy in premenopausal women due to insufficient long-term safety data [3].

Cognitive behavioral therapy (CBT) and mindfulness-based interventions have shown benefit in randomized trials. A 2018 meta-analysis in the Journal of Sexual Medicine found that psychological interventions improved sexual desire with a standardized mean difference of 0.48 (95% CI 0.32 to 0.64), comparable to pharmacological effect sizes [13].

Patients in non-U.S. jurisdictions who specifically want bremelanotide would need to explore personal importation rules, which vary by country. In the UK, the MHRA permits importation of a 3-month personal supply of an unlicensed medicine, but the prescriber must take clinical responsibility. Canadian regulations are more restrictive, generally requiring SAP authorization.